Revance Therapeutics (RVNC) Scheduled to Post Earnings on Thursday

Revance Therapeutics (NASDAQ:RVNC) will issue its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.66) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.17. The company had revenue of $69.80 million during the quarter, compared to the consensus estimate of $64.02 million. On average, analysts expect Revance Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Revance Therapeutics Trading Up 6.8 %

Shares of NASDAQ:RVNC opened at $4.38 on Wednesday. Revance Therapeutics has a 12-month low of $3.21 and a 12-month high of $37.98. The company has a market cap of $456.48 million, a PE ratio of -1.16 and a beta of 1.16. The stock has a 50 day moving average of $4.76 and a 200 day moving average of $6.21.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on RVNC. Piper Sandler reduced their price objective on shares of Revance Therapeutics from $42.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, February 29th. Barclays decreased their price target on Revance Therapeutics from $35.00 to $10.00 and set an “overweight” rating on the stock in a report on Monday, January 29th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Revance Therapeutics in a research note on Thursday, February 29th. Needham & Company LLC decreased their target price on Revance Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, February 29th. Finally, Mizuho downgraded Revance Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $16.00 to $9.00 in a research note on Monday, January 29th. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, Revance Therapeutics currently has an average rating of “Hold” and a consensus target price of $13.75.

Insiders Place Their Bets

In other news, CFO Tobin Schilke sold 9,361 shares of the stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $5.04, for a total transaction of $47,179.44. Following the completion of the transaction, the chief financial officer now directly owns 192,666 shares in the company, valued at approximately $971,036.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Revance Therapeutics news, insider Dwight Moxie sold 8,125 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $5.04, for a total transaction of $40,950.00. Following the sale, the insider now directly owns 137,815 shares in the company, valued at $694,587.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Tobin Schilke sold 9,361 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $5.04, for a total value of $47,179.44. Following the completion of the sale, the chief financial officer now directly owns 192,666 shares of the company’s stock, valued at $971,036.64. The disclosure for this sale can be found here. Insiders have sold a total of 29,089 shares of company stock valued at $143,642 in the last quarter. 3.50% of the stock is currently owned by insiders.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.